H1 2015 financial highlights
Group revenue of $709 million, in line with H1 2014 in constant currency or down 4% on a reported basis, with good performances from Branded and Injectables, offset by the expected decline in specific market opportunities in Generics
Full year Group revenue guidance maintained at around 6% growth in constant currency, or 2% on a reported basis
Group adjusted operating profit of $204 million, compared with $244 million in H1 2014,
Basic EPS of 67.3 cents per share, down 21%
Interim dividend of 11.0 cents per share, in line with total dividend paid in H1 2014
H1 2015 strategic highlights
Roxane acquisition will transform Hikma's US business, establishing Hikma as the sixth largest US generics company
Successful integration of Bedford is delivering new approvals for US Injectables
Inaugural bond issue raised $500 million, providing financial flexibility to support future growth
Partnership with Vitabiotics, announced today, broadens Hikma's MENA portfolio with leading OTC brands
New product introductions across all countries and markets - launched 40 products and received 118 product approvals, expanding and enhancing Hikma's global product portfolio
